By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities ...

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed promising efficacy in patients with advanced or metastatic endometrial cancer, ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created ...

Led by a team of distinguished toxicology experts, TriApex was thrilled to take part in this prestigious meeting, engaging in ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

These assets are engineered to produce minimal off-target toxicity, with a higher therapeutic ... to swiftly advance our portfolio of promising ADC assets," said David Lennon, President and ...